This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): INCB018424 (Oral), INC424, ruxolitinib, Jakavi (EU)
Description: BioMedTracker has separate drug profiles for INCB18424. Please also see INCB18424 (Topical).
INCB18424 is a janus-associated kinase (JAK) inhibitor. Its chemical name is (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate.
Deal Structure: INCB18424 was originally developed by Incyte.
Incyte and Novartis
In November 2009, Incyte announced that it entered into a collaboration and license agreement with Novartis for INCB18424.
Under the terms of the agreement, Incyte will retain exclusive rights for the development and potential commercialization of INCB18424 in the US. Novartis will have responsibility for the future development and commercialization of INCB18424 in all hematologyoncology indications outside of the US. Each company will be responsible for costs in their respective territories for INCB18424 with costs of collaborative studies shared equally. Novartis will make an upfront payment of $150 million to Incyte plus an immediate $60 million milestone payment for the initiation of the European Phase III trial of INCB18424, COMFORT-II, that began in July of 2009. Incyte may also be eligible over time for additional payments of up to approximately $1.1 billion if future contingent...See full deal structure in Biomedtracker
Partners: Novartis AG Eli Lilly & Company
Additional information available to subscribers only: